Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 4/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | HCK | P08631 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17909893 | 0.91 | SYK (0.41) | SYKKDRPIK3CBSRCPIK3CD | |
| SCHEMBL17909879 | 0.88 | SRC (0.40) | SYKKDM4EKDRPIK3CBSRC | |
| SCHEMBL18426557 | 0.85 | SRC (0.39) | SYKKDM4EKDRPIK3CBSRC | |
| SCHEMBL17909857 | 0.84 | NQO1 (0.41) | SYKKDM4ESRCPARP1HSP90AA1 | |
| SCHEMBL18426258 | 0.83 | TGFBR1 (0.42) | SYKKDRSRCABL1HSP90AA1 | |
| SCHEMBL17909864 | 0.83 | SYK (0.48) | SYKKDM4ELMNAPOLBCASP6 | |
| SCHEMBL16487124 | 0.82 | SYK (0.43) | SYKKDM4ELMNAPOLBCASP6 | |
| SCHEMBL17909837 | 0.81 | HSP90AA1 (0.48) | KDM4EKDRPIK3CBPARP1CYP1A2 | |
| SCHEMBL18425806 | 0.79 | ATR (0.45) | SYKPIK3CDPIK3CA | |
| SCHEMBL18425028 | 0.79 | HSP90AA1 (0.41) | KDM4EPIK3CBPARP1HSP90AA1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021463-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200031799-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-10308637-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-06-04 | — | — | US | disclosed |
| US-10266515-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-04-23 | — | — | US | disclosed |
| US-10259803-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-04-16 | — | — | US | disclosed |
| US-20190002437-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
| US-10023557-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2018-07-17 | — | — | US | disclosed |
| US-20180170906-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20170260163-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9611252-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2017-04-04 | — | — | US | disclosed |
| US-20170029406-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2017-02-02 | — | — | US | disclosed |
| US-20160200704-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2016-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308637-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | SYK 1810/4885KDM4E 798/4885LMNA 2032/4885 |
| US-20170029406-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | SYK 1810/4885KDM4E 798/4885LMNA 2032/4885 |
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | SYK 1810/4885KDM4E 798/4885LMNA 2032/4885 |
| US-20200031799-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | SYK 1810/4885KDM4E 798/4885LMNA 2032/4885 |
| US-20180170906-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | SYK 1810/4885KDM4E 798/4885LMNA 2032/4885 |
| US-10023557-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | SYK 1810/4885KDM4E 798/4885LMNA 2032/4885 |
| US-20170260163-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | SYK 1810/4885KDM4E 798/4885LMNA 2032/4885 |
| US-20160200704-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | SYK 1810/4885KDM4E 798/4885LMNA 2032/4885 |
| US-10266515-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | SYK 1810/4885KDM4E 798/4885LMNA 2032/4885 |
| US-10259803-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | SYK 1810/4885KDM4E 798/4885LMNA 2032/4885 |
| US-20190002437-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | SYK 1810/4885KDM4E 798/4885LMNA 2032/4885 |
| US-11021463-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | SYK 1810/4885KDM4E 798/4885LMNA 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.